A practical reference on alpha-MSH analogue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-20 and is reviewed periodically as new material appears.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Solid-state storage | -20 degrees Celsius or lower | Desiccated and protected from light |
| Solution stability | Short and method-dependent | Confirm by stability testing |
| Purity assessment | Reversed-phase HPLC | Reported as area percent |
| Identity confirmation | LC-MS or comparable method | Mass match against expected value |
| Common synonyms | MT-II; melanotan II | Informal and catalogue names |
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Documents seized during the 2011 operation that killed bin Laden included notes handwritten by bin Laden in September 2002 with the heading "The Birth of the Idea of September 11." He describes how he was inspired by the crash of EgyptAir Flight 990 in October 1999, which was deliberately crashed by co-pilot Gameel Al-Batouti, killing more than 200 passengers. "This is how the idea of 9/11 was conceived and developed in my head, and that is when we began the planning" bin Laden continued, adding that no one but Mohammed Atef and Abu al-Khair knew about it at the time. The 9/11 Commission Report identified Khalid Sheikh Mohammed as the architect of 9/11, but he is not mentioned in bin Laden's notes.
=== Contract research organizations === Contract research organizations (CROs) provide services to the life science industries along product development. There are more than 2000 CROs operating worldwide, representing revenues of more than $20 billion. There is a key difference between "Product" and "Patient" CROs. Whereas the production sites of CMOs are multipurpose plants, allowing for the production of tens to hundreds of tons of fine chemicals, the work places of patient CROs are the test persons for the clinical trials, and the work places of product CROs are the laboratory benches. Major customers for CRO services are the large global pharmaceutical companies. Half a dozen companies (Pfizer, GlaxoSmithKline, Sanofi-Aventis, AstraZeneca, Johnson & Johnson, and Merck & Co.) alone absorb about one third of all CRO spending. Similarly to CMOs, biotech start-up CROS, with their dichotomy between ambitious drug development programs and limited resources, are the second most promising prospects. Product CROs primarily provide sample preparation, process research and development services. Pilot plants, which produce 100 kg quantities, are combinations of development CROs and CMOs, and ae part of the arsenal of both types of enterprise. Tere are more 100 Product CROs. Most of them are privately held and have revenues of $10–$20 million per year or less, adding up to a total business in the range of $1.5-$2 billion. Examples include:
Nonetheless, it retains clinically meaningful opioid activity, contributing to its analgesic effects. Commercial formulations contain only the (R,R)-stereoisomer. Drugs with high MOR affinity, such as tapentadol, carry an abuse potential comparable to other strong opioids like morphine, oxycodone, and hydromorphone.
N-Desethylfluornitrazene (DFNZ or D-FNZ) is an atypical opioid analgesic of the nitazene family related to etonitazene. It is the N-desethyl analogue of fluornitazene (FNZ). DFNZ is the major active metabolite of FNZ, which appears to act as a prodrug of DFNZ. The drug is a highly selective superagonist of the μ-opioid receptor (MOR), with an affinity (Ki) of 1.0 nM, an EC50Tooltip half-maximal effective concentration of 1.66 to 8.49 nM, and an EmaxTooltip maximal efficacy of 104 to 119%. It shows some biased agonism at the MOR, preferring G protein to β-arrestin signaling. DFNZ shows a unique spatiotemporal pattern of MOR activation in vivo. It exhibits central permeability, but has impaired brain penetrance and thus some peripheral selectivity. The drug is a substrate of both P-glycoprotein and breast cancer resistance protein (BCRP), in contrast to FNZ, and this is responsible for its reduced capacity to cross the blood–brain barrier. Due to its peripheral selectivity, it shows limited MOR occupancy in the brain in rodents. DFNZ produces strong analgesic effects in rodents. It also produces antiallodynic effects, induces hyperlocomotion, and substitutes for heroin, thereby reducing heroin self-administration. Conversely, the drug does not produce respiratory depression, does not cause brain hypoxia at analgesic doses, does not downregulate the MOR, produces little or no tolerance and withdrawal, and shows weak reinforcing effects in rodents.
A synovial joint, also known as diarthrosis, joins bones or cartilage with a fibrous joint capsule that is continuous with the periosteum of the joined bones, constitutes the outer boundary of a synovial cavity, and surrounds the bones' articulating surfaces. This joint unites long bones and permits free bone movement and greater mobility. The synovial cavity/joint is filled with synovial fluid. The joint capsule is made up of an outer layer of fibrous membrane, which keeps the bones together structurally, and an inner layer, the synovial membrane, which seals in the synovial fluid. They are the most common and most movable type of joint in the body. As with most other joints, synovial joints achieve movement at the point of contact of the articulating bones. Joints that are not synovial include fibrous joints such as the joints in the cranium, and cartilaginous joints such as intervertebral discs. Synovial joints originated 400 million years ago in the first jawed vertebrates.
Sources: en.wikipedia.org
==== Abhidharma interpretations ==== Prayudh Payutto notes that in Buddhaghosa's Sammohavinodani, a commentary to the Vibhaṅga, the principle of dependent origination is explained as occurring entirely within the space of one mind moment. Furthermore, according to Payutto, there is material in the Vibhaṅga which discusses both models, the three lifetimes model (at Vibh.147) and the one mind moment model. Similarly, Cox notes that the Sarvastivadin Vijñānakāya contains two interpretations of dependent origination, one which explains the 12 nidanas as functioning in a single moment as a way to account for ordinary experience and another interpretation that understands the 12 nidanas as arising sequentially, emphasizing their role in the functioning of rebirth and karma. Wayman notes that an interpretation referring to mental processes (referred to as dependent origination with a transient character) can also be found in northern sources, such as the Jñānaprasthāna, the Arthaviniscaya-tika and the Abhidharmakosa (AKB.III.24d). The Jñānaprasthāna, explains the nidanas with the example of the act of killing. Ignorance leads to the motivation to kill, which is acted on through consciousness, name and form and so on. This leads to mental karma being generated (bhava) which leads to the movement of the hand to kill (birth). The different interpretations of dependent origination as understood in the northern tradition can be found in the Abhidharmakosa, which outlines three models of the twelve nidanas:
== Market and consumption == The USDA estimated the output of Bangladesh's food industry at US$8.0 billion for calendar year 2025. Its consumer-oriented food-market figures separately estimated a domestic market of US$9.6 billion, imports of US$2.0 billion and exports of US$0.4 billion. These figures describe different parts of the food market and are not equivalent to the value of the food-processing sector. A separate estimate presented by the Centre for Policy Dialogue in 2025, citing data from the Bangladesh Investment Development Authority, valued the narrower packaged-food market at about US$4.8 billion and projected it to reach US$5.8 billion by 2030. Urbanisation and changing consumption patterns have increased demand for convenience foods. The USDA identified snacks, ready-to-eat meals, frozen foods, beverages and dairy products among common processed-food categories and reported increasing demand for safe and higher-quality food products. Modern food retail remains a relatively small part of Bangladesh's retail market but has expanded. The USDA reported more than 1,500 supermarket-chain outlets and around 1,500 smaller outlets in 2026, with annual modern food-retail turnover estimated at US$800 million. It estimated that modern retail accounted for about 3 to 4 percent of total retail sales.
== Nuclear processes == A nuclide is considered to "exist" if it has a half-life greater than 2 ×10−14s. This is an arbitrary boundary; shorter half-lives are considered resonances, such as a system undergoing a nuclear reaction. This time scale is characteristic of the strong interaction which creates the nuclear force. Only nuclides are considered to decay and produce radioactivity. Nuclides can be stable or unstable. Unstable nuclides decay, possibly in several steps, until they become stable. There are 251 known stable nuclides. The number of unstable nuclides discovered has grown, with about 3000 known in 2006. The most common and consequently historically the most important forms of natural radioactive decay involve the emission of alpha-particles, beta-particles, and gamma rays. Each of these correspond to a fundamental interaction predominantly responsible for the radioactivity:
Emerging methods for single-cell mass-spectrometry analysis promise to enable studying signal transduction with single-cell resolution. In notch signaling, direct contact between cells allows for precise control of cell differentiation during embryonic development. In the worm Caenorhabditis elegans, two cells of the developing gonad each have an equal chance of terminally differentiating or becoming a uterine precursor cell that continues to divide. The choice of which cell continues to divide is controlled by competition of cell surface signals. One cell will happen to produce more of a cell surface protein that activates the Notch receptor on the adjacent cell. This activates a feedback loop or system that reduces Notch expression in the cell that will differentiate and that increases Notch on the surface of the cell that continues as a stem cell.
== Career == Appointed by the Federal Decree No. (91) of 2006 issued by His Highness the Head of State for National Security Advisor. Vice President of the Executive Council of Abu Dhabi Emirate. Chairman of the Emirates Identity Authority. Al Ain Club Chairman of Board of Directors Vice-president of the executive board and of the honorary board Abu Dhabi Sports Council, chairman Abu Dhabi Combat Club, president In 2006, he was elected as Chairman of First Gulf Bank. He succeeded to the chairman position from Sheikh Mansour bin Zayed Al Nahyan, his other brother. On 12 December 2010, he was appointed a member of Executive Council of Abu Dhabi.
Sources: en.wikipedia.org
==== Trilayer ==== An electric field can change trilayer graphene's crystal structure, transforming its behavior from metal-like into semiconductor-like. A sharp metal scanning tunneling microscopy tip was able to move the domain border between the upper and lower graphene configurations. One side of the material behaves as a metal, while the other side behaves as a semiconductor. Trilayer graphene can be stacked in either Bernal or rhombohedral configurations, which can exist in a single flake. The two domains are separated by a precise boundary at which the middle layer is strained to accommodate the transition from one stacking pattern to the other. Silicon transistors are either p-type or n-type, whereas graphene can operate as both. This lowers costs and is more versatile. The technique provides the basis for a field-effect transistor. In trilayer graphene, the two stacking configurations exhibit different electronic properties. The region between them consists of a localized strain soliton where the carbon atoms of one graphene layer shift by the carbon–carbon bond distance. The free-energy difference between the two stacking configurations scales quadratically with electric field, favoring rhombohedral stacking as the electric field increases. This ability to control the stacking order opens the way to new devices that combine structural and electrical properties.
As a pioneer of a self-reflexive sociology who prefigured Bourdieu's ability to factor in the effect of reflection on the societal object, Adorno realized that some criticism (including deliberate disruption of his classes in the 1960s) could never be answered in a dialogue between equals if, as he seems to have believed, what the naïve ethnographer or sociologist thinks of a human essence is always changing over time.
Transmitter uptake and release: Astrocytes express plasma membrane transporters for several neurotransmitters, including glutamate, ATP, and GABA. More recently, astrocytes were shown to release glutamate or ATP in a vesicular, Ca2+-dependent manner. (This has been disputed for hippocampal astrocytes.) Regulation of ion concentration in the extracellular space: Astrocytes express potassium channels at a high density. When neurons are active, they release potassium, increasing the local extracellular concentration. Because astrocytes are highly permeable to potassium, they rapidly clear the excess accumulation in the extracellular space. If this function is interfered with, the extracellular concentration of potassium will rise, leading to neuronal depolarization by the Goldman equation. Abnormal accumulation of extracellular potassium is well known to result in epileptic neuronal activity. Trace metal homeostasis: Astrocytes are the principal regulators of trace metal homeostasis in the central nervous system. They serve as the main storage and distribution sites for copper, manganese, zinc and iron, protecting neurons from metal-induced toxicity while supplying these essential cofactors. Astrocytes accumulate copper efficiently via the high-affinity transporter CTR1 and store it bound to glutathione and metallothioneins. They export copper via the copper-transporting ATPase ATP7A, thereby supplying copper to neighbouring neurons. Astrocytes are the main storage site for manganese in the brain, accumulating roughly 50 times more Mn²⁺ than neurons.
Following diagnosis, the extent of the disease should be established regarding the heart, the lungs, and the muscles/bones (musculoskeletal). Metabolic functions should also be assessed, as lipodystrophy can co-occur with EDMD, by measuring levels of sugar, cholesterol, and triglycerides in the blood. Tests useful for heart evaluation include electrocardiography (EKG), echocardiography (echo), cardiac MRI, and electrophysiology studies. Musculoskeletal function can be assessed by a physical therapist or orthopedist. Regardless of the extent of the disease, cardiac and respiratory complications should be monitored. EKG, holter, and echo are recommended yearly, and additional tests can be indicated depending on heart involvement. Pulmonary function tests (PFTs) are recommended every 2–3 years, or yearly in those with respiratory involvement. Although the root cause of EDMD is not currently treatable, its manifestations and complications can be treated. Heart involvement can be addressed with medications (antiarrhythmics, beta-blockers, and ACE inhibitors), pacemakers, defibrillators, and sometimes heart transplantation. Affecting breathing can be addressed with physical therapy and, later in the disease, mechanical ventilation. Contractures and scoliosis can be addressed with orthopedic surgery. Mobility can be improved with physical therapy, occupational therapy, and mechanical aids (canes, orthoses, wheelchairs).
Sources: en.wikipedia.org
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.
There is no single harmonised standard governing these products, and manufacturing conditions differ. Impurities may include truncated sequences, oxidation products, residual solvents, and counter-ions. Independent testing is often the only way to characterise a given lot.
Reported studies have looked at pigmentation, photoprotection, and metabolic or appetite-related endpoints in small experimental settings. Much of the evidence base is early-stage and limited in size. Questions about long-term effects and clinical relevance remain open.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.